13F Holdings
中文EN

BNTX BioNTech SE IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1776985 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY4.3%
TTM net income YoY-70.8%
TTM EPS YoY-69.7%
Revenue 3-yr CAGR-45.1%
Net income 3-yr CAGR—

Margins

Gross margin77.6%
Operating margin-49.0%
Net margin-39.6%
FCF margin9.8%
EBITDA margin-35.6%

Returns

ROE-5.9%
ROA-5.1%
ROIC (approx.)-10.5%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets12.6%
Debt / equity0.00x
Current ratio7.54x
Interest coverage-98.94x

Cash quality & payout

Operating cash flow / net income-0.40x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue6.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue2.87B2.75B3.82B17.31B18.98B
Cost of revenue641.80M541.30M599.80M3.00B2.91B
Gross profit2.23B2.21B3.22B14.32B16.07B
R&D expense2.10B2.25B1.78B1.54B949.20M
SG&A expense514.40M531.10M495.00M481.70M276.80M
Operating income-1.40B-1.31B690.40M12.64B15.28B
Interest expense14.20M16.90M7.50M18.90M305.10M
Pretax income-1.05B-677.70M1.19B12.95B15.05B
Income tax85.30M-12.40M255.80M3.52B4.75B
Net income-1.14B-665.30M930.30M9.43B10.29B
EBITDA-1.02B-1.02B873.80M12.77B15.36B
EPS (basic)-4.70-2.773.8738.7842.18
EPS (diluted)-4.70-2.773.8337.7739.63
Weighted avg. shares (diluted)241.70M240.40M242.70M249.80M259.70M
Balance sheet
Cash & equivalents7.68B9.76B11.66B13.88B1.69B
Receivables924.20M1.46B2.16B7.15B12.38B
Inventory110.70M283.30M357.70M439.60M502.50M
Current assets16.15B18.80B19.53B21.92B15.07B
PP&E, netmay include right-of-use assets (IFRS)1.08B935.30M757.20M609.20M322.50M
Goodwill367.90M380.60M362.50M61.20M57.80M
Total assets21.99B22.53B23.01B23.28B15.83B
Current liabilities2.14B2.52B2.07B2.95B3.48B
Short-term debt————129.90M
Long-term debt————171.60M
Total debt————301.50M
Total liabilities2.76B3.12B2.76B3.22B3.94B
Shareholders' equity19.22B19.41B20.25B20.06B11.89B
Net debt————-1.39B
Shares outstanding251.33M239.97M237.73M243.22M242.52M
Cash flow statement
Operating cash flow456.00M207.70M5.37B13.58B889.70M
Capital expenditure175.10M286.50M249.40M329.20M127.50M
Free cash flow280.90M-78.80M5.12B13.25B762.20M
Investing cash flow-2.47B-2.08B-6.95B-35.30M-566.10M
Financing cash flow-52.90M-45.90M-778.60M-1.42B94.20M
Depreciation & amortization382.80M298.00M183.40M123.30M75.20M
Stock-based compensation106.20M100.90M51.40M108.60M93.90M
Dividends paid—00484.30M0

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.